Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL
- 23 April 2026
- journal article
- Published by American Society of Hematology in Blood
- Vol. 147 (17) , 2011-2017
Abstract
In a real-world analysis of brexucabtagene autoleucel recipients with relapsed/refractory B-cell acute lymphoblastic leukemia (N = 278), lack of response to prior blinatumomab correlates with significantly worse following chimeric antigen receptor T-cell therapy outcomes.Keywords
This publication has 24 references indexed in Scilit:
- IKAROS levels are associated with antigen escape in CD19- and CD22-targeted therapies for B-cell malignanciesNature Communications, 2025
- Sequencing antigen‐targeting antibodies and cellular therapies in adults with relapsed/refractory B‐cell acute lymphoblastic leukemiaAmerican Journal of Hematology, 2023
- Extramedullary disease relapse and progression after blinatumomab therapy for treatment of acute lymphoblastic leukemiaCancer, 2021
- KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 studyThe Lancet, 2021
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsTransplantation and Cellular Therapy, 2019
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2018
- CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatmentBlood Cancer Journal, 2017
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2017
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 studyThe Lancet Oncology, 2015